AstraZeneca bolstered by Seroquel patent victory

A court in New Jersey granted AstraZeneca's motion for summary judgment on the basis of no inequitable conduct, making unnecessary a trial that had been slated to begin on August 11.

AstraZeneca had sued both Teva Pharmaceutical Industries and Sandoz, the generics arm of Novartis , alleging their plans to launch generic versions of Seroquel infringed its patents.
Teva and Sandoz had already conceded infringement and the validity of AstraZeneca's patent, so only the issue of inequitable conduct remained to be resolved.

"We are pleased with the court's decision to uphold our valid intellectual property. Seroquel remains an important part of our company's portfolio," AstraZeneca Chief Executive David Brennan said in a statement.

The details can be read here.

The whole Judgement can be read here.